Next Article in Journal
A Fresh Look at Islet Isolation from Rabbit Pancreases
Previous Article in Journal
Histopathological and Immunohistochemical Characteristics of Different Types of Cardiac Amyloidosis
Previous Article in Special Issue
Psychobiotic Properties of Lactiplantibacillus plantarum in Neurodegenerative Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 19
10.3390/ijms251910668
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways

by
Ting Zhang
,
Chang Liu
,
Ning Zhong
,
Yichen Wang
,
Yiyun Huang
and
Xiaoqin Zhang
*
Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(19), 10668; https://doi.org/10.3390/ijms251910668
Submission received: 20 August 2024 / Revised: 29 September 2024 / Accepted: 1 October 2024 / Published: 3 October 2024
(This article belongs to the Special Issue Molecular Insights into Neurotrophins and Neuropsychiatric Disorders)
Versions Notes

Abstract

Cognitive impairment is a core feature of schizophrenia, playing a pivotal role in the pathogenesis and prognosis of this disorder. Cognitive impairment in schizophrenia encompasses a wide range of domains, including processing speed, episodic memory, working memory, and executive function. These deficits persist throughout the course of the illness and significantly impact functional outcomes and quality of life. Therefore, it is imperative to identify the biological basis of cognitive deficits in schizophrenia and develop effective treatments. The role of N-methyl-D-aspartate (NMDA) receptors in synaptic transmission and plasticity has long been recognized, making them potential targets for schizophrenia treatment. This review will focus on emerging pharmacology targeting NMDA receptors, offering strategies for the prevention and treatment of cognitive deficits in schizophrenia.
Keywords: NMDA receptor; cognitive impairment; excitation/inhibition balance; schizophrenia NMDA receptor; cognitive impairment; excitation/inhibition balance; schizophrenia

Share and Cite

MDPI and ACS Style

Zhang, T.; Liu, C.; Zhong, N.; Wang, Y.; Huang, Y.; Zhang, X. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. Int. J. Mol. Sci. 2024, 25, 10668. https://doi.org/10.3390/ijms251910668

AMA Style

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences. 2024; 25(19):10668. https://doi.org/10.3390/ijms251910668

Chicago/Turabian Style

Zhang, Ting, Chang Liu, Ning Zhong, Yichen Wang, Yiyun Huang, and Xiaoqin Zhang. 2024. "Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways" International Journal of Molecular Sciences 25, no. 19: 10668. https://doi.org/10.3390/ijms251910668

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop